NextCure (NXTC) Revenue (2019 - 2020)
NextCure (NXTC) posted Revenue of $22.4 million for Q1 2020, up 1016.11% on a QoQ basis from $2.0 million in Q4 2019, and up 1549.08% year-over-year from $1.4 million in Q2 2019.
Powered by 
Analysis
NextCure (NXTC) Revenue (2019 - 2020) Analysis & Trends
NextCure has reported Revenue for 2 years, with the latest figure at $22.4 million in Q1 2020.
- On a quarterly basis, Revenue rose 1549.08% year-over-year to $22.4 million in Q1 2020; TTM through Dec 2020 was $22.4 million, a 252.58% increase from a year earlier, with the FY2020 full-year figure at $22.4 million, up 252.58% from the prior year.
- Revenue was $22.4 million for Q1 2020 at NextCure, up from $2.0 million in the prior quarter.
- The five-year high for Revenue was $22.4 million in Q1 2020, with the low at $1.4 million in Q1 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 10.05 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 7.80 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 3.33 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 4.29 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 145.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 2.74 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 1.44 Mn |
| 10 | NextCure | 37.91 Mn | 37.91 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2020 | 22.38 Mn |
| Dec 31, 2019 | 2.01 Mn |
| Sep 30, 2019 | 1.58 Mn |
| Jun 30, 2019 | 1.40 Mn |
| Mar 31, 2019 | 1.36 Mn |